Lantheus (LNTH) Competitors

Lantheus (NASDAQ:LNTH) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Which has stronger valuation & earnings, LNTH or GMAB?

Genmab A/S has higher revenue and earnings than Lantheus. Genmab A/S is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.53B	2.58	$312.44M	$3.76	15.48
Genmab A/S	$3.12B	5.06	$1.14B	$1.99	12.39

Which has more risk and volatility, LNTH or GMAB?

Lantheus has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.

Is LNTH or GMAB more profitable?

Genmab A/S has a net margin of 37.53% compared to Lantheus' net margin of 17.82%. Lantheus' return on equity of 34.06% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.82%	34.06%	19.10%
Genmab A/S	37.53%	21.03%	16.98%

Do analysts prefer LNTH or GMAB?

Lantheus presently has a consensus price target of $105.50, suggesting a potential upside of 81.24%. Genmab A/S has a consensus price target of $37.60, suggesting a potential upside of 52.54%. Given Lantheus' stronger consensus rating and higher probable upside, equities analysts plainly believe Lantheus is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Does the media refer more to LNTH or GMAB?

In the previous week, Lantheus had 6 more articles in the media than Genmab A/S. MarketBeat recorded 15 mentions for Lantheus and 9 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.70 beat Lantheus' score of 0.55 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders hold more shares of LNTH or GMAB?

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Lantheus shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Genmab A/S beats Lantheus on 9 of the 17 factors compared between the two stocks.